Prognostic value of cardiac troponins in case of COVID-19


DOI: https://dx.doi.org/10.18565/therapy.2022.3.91-100

Alieva A.M., Reznik E.V., Teplova N.V., Batov M.A., Shnahova L.M., Arakelyan R.A., Baykova I.E., Totolyan G.G., Volynkina V.M., Kislyakov V.A., Nikitin I.G.

1) N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia, Moscow; 2) P.A. Herzen Moscow Scientific and Research Oncological Institute of Oncology – a branch of National Medical Research Center for Radiology; 3) I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University)
Abstract. Despite pulmonary tropism of SARS-CoV-2, COVID-19 has a very high risk of multiple organ failure development, including cardiovascular system damage. The possible mechanisms underlying myocardial injury in patients with COVID-19 are not fully understood, but are most likely multifactorial. Myocardial damage may be caused due to the direct effect of the virus on endothelial cells and cardiomyocytes, mediated by the angiotensin-converting enzyme 2 receptor. Myocardial involvement may also be due to the development of a «cytokine storm» and apoptosis of cardiomyocytes. Also, ischemic damage and even myocardial infarction can be the result of shock, hypoxia of various origins and prolonged tachycardia. Biomarkers of acute myocardial injury have shown their value as a laboratory prognostication tool in COVID-19 patients. Elevated serum troponin levels are correlated with health deterioration and increased mortality of patients with and without heart disease. Whether myocardial damage is the cause of the worsening of COVID-19 or a consequence of the progression of this disease is not completely clear, in our review we have only highlighted its possible mechanisms.
Keywords: COVID-19, troponin, cardiovascular complications, cardiovascular disease
Read entire article

Literature

1. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020; 5(4): 536–44. https://dx.doi.org/10.1038/ s41564-020-0695-z.


2. Zhu N., Zhang D., Wang W. et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020; 382(8): 727–33. https://dx.doi.org/10.1056/NEJMoa2001017.


3. Li X., Geng M., Peng Y. et al. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020; 10(2): 102–8. https://dx.doi.org/10.1016/j.jpha.2020.03.001.


4. Jackson C., Farzan M., Chen B., Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol. 2022; 23(1): 3–20. https://dx.doi.org/10.1038/s41580-021-00418-x.


5. Tai W., He L., Zhang X. et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 2020; 17(6): 613–20. https://dx.doi.org/10.1038/s41423-020-0400-4.


6. Junyi G., Zheng H., Li L., Jiagao L. Coronavirus disease 2019 (COVID-19) and cardiovascular disease: A viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection. J Am Heart Assoc. 2020; 9(7): e016219. https://dx.doi.org/10.1161/JAHA.120.016219.


7. Aboughdir M., Kirwin T., Abdul Khader A., Wang B. Prognostic value of cardiovascular biomarkers in COVID-19: A review. Viruses. 2020; 12(5): 527. https://dx.doi.org/10.3390/v12050527.


8. Полонская Я.В., Каштанова Е.В., Стахнева Е.М. с соавт. COVID-19 и сердечно-сосудистые заболевания. Атеросклероз. 2020; 2: 73–79. [Polonskaya Ya.V., Kashtanova E.V., Stakhneva E.M. et al. COVID-19 and cardiovascular disease. Ateroskleroz = Atherosclerosis. 2020; 2: 73–79 (In Russ.)]. https://dx.doi.org/10.15372/ATER20200207.


9. Бубнова М.Г., Аронов Д.М. COVID-19 и сердечно-сосудистые заболевания: от эпидемиологии до реабилитации. Пульмонология. 2020; 5: 688–699. [Bubnova M.G., Aronov D.M. COVID-19 and cardiovascular disease: from epidemiology to rehabilitation. Pul'monologiya = Pulmonology. 2020; 5: 688–699 (In Russ.)]. https://dx.doi.org/10.18093/0869-0189-2020-30-5-688-699.


10. Guan W.J., Liang W.H., Zhao Y. et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: A nationwide analysis. Eur Respir J. 2020; 55(5): 2000547. https://dx.doi.org/10.1183/13993003.00547-2020.


11. Richardson S., Hirsch J.S., Narasimhan M. et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020; 323(20): 2052–59. https://dx.doi.org/10.1001/jama.2020.6775. Erratum in: JAMA. 2020; 323(20): 2098.


12. Onder G., Rezza G., Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020; 323(18): 1775–76. https://dx.doi.org/10.1001/jama.2020.4683.


13. Глыбочко П.В., Фомин В.В., Авдеев С.Н. с соавт. Клиническая характеристика 1007 больных тяжелой SARS-CoV-2-пневмонией, нуждавшихся в респираторной поддержке. Клиническая фармакология и терапия. 2020; 2: 21–29. [Glybochko P.V., Fomin V.V., Avdeev S.N. et al. Clinical characteristics of 1007 patients with severe SARS-CoV-2 pneumonia requiring respiratory support. Klinicheskaya farmakologiya i terapiya = Clinical Pharmacology and Therapy. 2020; 2: 21–29 (In Russ.)]. https://dx.doi.org/10.32756/0869-5490-2020-2-21-29.


14. Zhou F., Yu T., Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020; 395(10229): 1054–62. https://dx.doi.org/10.1016/S0140-6736(20)30566-3.


15. Mueller C., Giannitsis E., Jaffe A.S. et al. Cardiovascular biomarkers in patients with COVID-19. Eur Heart J Acute Cardiovasc Care. 2021; 10(3): 310–19. https://dx.doi.org/10.1093/ehjacc/zuab009.


16. Clerkin K.J., Fried J.A., Raikhelkar J. et al. COVID-19 and cardiovascular disease. circulation. 2020; 141(20): 1648–55. https://dx.doi.org/10.1161/CIRCULATIONAHA.120.046941.


17. Zheng Y.Y., Ma Y.T., Zhang J.Y., Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020; 17(5): 259–60. https://dx.doi.org/10.1038/s41569-020-0360-5.


18. Lala A., Johnson K.W., Januzzi J.L. et al. Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection. J Am Coll Cardiol. 2020; 76(5): 533–46. https://dx.doi.org/10.1016/j.jacc.2020.06.007.


19. Flores D., Walter J., Wussler D. et al. Direct comparison of high-sensitivity cardiac troponin T and I for prediction of mortality in patients with pneumonia. J Clin Chem Lab Med. 2019; 2: 131.


20. Shi S., Qin M., Shen B. et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020; 5(7): 802–10. https://dx.doi.org/10.1001/jamacardio.2020.0950.


21. Meyer P., Degrauwe S., Van Delden C. et al. Typical takotsubo syndrome triggered by SARS-CoV-2 infection. Eur Heart J. 2020; 41(19): 1860. https://dx.doi.org/10.1093/eurheartj/ehaa306.


22. Duan J., Wu Y., Liu C. et al. Deleterious effects of viral pneumonia on cardiovascular system. Eur Heart J. 2020; 41(19): 1833–38. https://dx.doi.org/10.1093/eurheartj/ehaa325.


23. Basso C., Leone O., Rizzo S. et al. Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study. Eur Heart J. 2020; 41(39): 3827–35. https://dx.doi.org/10.1093/eurheartj/ehaa664.


24. Wallentin L., Lindbäck J., Eriksson N. et al. Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. Eur Heart J. 2020; 41(41): 4037–46. https://dx.doi.org/10.1093/eurheartj/ehaa697.


25. Fauvel C., Weizman O., Trimaille A. et al. Pulmonary embolism in COVID-19 patients: A French multicentre cohort study. Eur Heart J. 2020; 41(32): 3058–68. https://dx.doi.org/10.1093/eurheartj/ehaa500.


26. Parohan M., Yaghoubi S., Seraji A. Cardiac injury is associated with severe outcome and death in patients with Coronavirus disease 2019 (COVID-19) infection: A systematic review and meta-analysis of observational studies. Eur Heart J Acute Cardiovasc Care. 2020; 9(6): 665–77. https://dx.doi.org/10.1177/2048872620937165.


27. Sandoval Y., Januzzi J.L., Jaffe A.S. Cardiac troponin for assessment of myocardial injury in COVID-19: JACC review topic of the week. J Am Coll Cardiol. 2020; 76(10): 1244–58. https://dx.doi.org/10.1016/j.jacc.2020.06.068.


28. Shi S., Qin M., Cai Y. et al. Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019. Eur Heart J. 2020; 41(22): 2070–79. https://dx.doi.org/10.1093/eurheartj/ehaa408.


29. Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223): 497–506. https://dx.doi.org/10.1016/S0140-6736(20)30183-5.


30. Lippi G., Lavie C.J., Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis. Prog Cardiovasc Dis. 2020; 63(3): 390–91. https://dx.doi.org/10.1016/j.pcad.2020.03.001.


31. Guo T., Fan Y., Chen M. et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020; 5(7): 811–18. https://dx.doi.org/10.1001/jamacardio.2020.1017.


32. Tuo H., Li W., Tang L. et al. Cardiac biomarker abnormalities are closely related to prognosis in patients with COVID-19. Int Heart J. 2021; 62(1): 148–52. https://dx.doi.org/10.1536/ihj.20-180.


33. De Michieli L., Ola O., Knott J.D. et al. High-sensitivity cardiac troponin T for the detection of myocardial injury and risk stratification in COVID-19. Clin Chem. 2021; 67(8): 1080–89. https://dx.doi.org/10.1093/clinchem/hvab062.


34. Cordeanu E.M., Duthil N., Severac F. et al. Prognostic value of troponin elevation in COVID-19 hospitalized patients. J Clin Med. 2020; 9(12): 4078. https://dx.doi.org/10.3390/jcm9124078.


35. Cremer S., Jakob C., Berkowitsch A.et al. Elevated markers of thrombo-inflammatory activation predict outcome in patients with cardiovascular comorbidities and COVID-19 disease: insights from the LEOSS registry. Clin Res Cardiol. 2021; 110(7): 1029–40. https://dx.doi.org/10.1007/s00392-020-01769-9.


36. Calvo-Fernandez A., Izquierdo A., Subirana I. et al. Markers of myocardial injury in the prediction of short-term COVID-19 prognosis. Rev Esp Cardiol (Engl Ed). 2021; 74(7): 576–83. https://dx.doi.org/10.1016/j.rec.2020.09.011.


37. Gullu U.U., Gungor S., Ipek S. et al. Predictive value of cardiac markers in the prognosis of COVID-19 in children. Am J Emerg Med. 2021; 48: 307–11. https://dx.doi.org/10.1016/j.ajem.2021.06.075.


38. Valverde I., Singh Y., Sanchez-de-Toledo J. et al. Acute cardiovascular manifestations in 286 children with multisystem inflammatory syndrome associated with COVID-19 infection in Europe. Circulation. 2021; 143(1): 21–32. https://dx.doi.org/10.1161/CIRCULATIONAHA.120.050065.


39. Majure D.T., Gruberg L., Saba S.G. et al. Usefulness of elevated troponin to predict death in patients with COVID-19 and myocardial injury. Am J Cardiol. 2021; 138: 100–6. https://dx.doi.org/10.1016/j.amjcard.2020.09.060.


40. Ozyılmaz S., Ergun Alis E., Ermiş E. et al. Assessment of the relationship between mortality and troponin I levels in hospitalized patients with the novel coronavirus (COVID-19). Medicina (Kaunas). 2020; 56(12): 693. https://dx.doi.org/10.3390/medicina56120693.


41. Peiro O.M., Carrasquer A., Sanchez-Gimenez R. et al. Biomarkers and short-term prognosis in COVID-19. Biomarkers. 2021; 26(2): 119–26. https://dx.doi.org/10.1080/1354750X.2021.1874052.


42. Maino A., Di Stasio E., Grimaldi M.C. et al. Prevalence and characteristics of myocardial injury during COVID-19 pandemic: A new role for high-sensitive troponin. Int J Cardiol. 2021; 338: 278–85. https://dx.doi.org/10.1016/j.ijcard.2021.06.028.


43. Ruge M., Gomez J., du Fay de Lavallaz J. et al. The prognostic value of cardiac troponin for 60-day mortality and major adverse events in COVID-19 patients. Cardiovasc Pathol. 2021; 55: 107374. https://dx.doi.org/10.1016/j.carpath.2021.107374.


44. Zwaenepoel B., Dhont S., Hoste E. et al. The prognostic value of cardiac biomarkers and echocardiography in critical COVID-19. Front Cardiovasc Med. 2021; 8: 752237. https://dx.doi.org/10.3389/fcvm.2021.752237.


45. Manocha K.K., Kirzner J., Ying X. et al. Troponin and other biomarker levels and outcomes among patients hospitalized with COVID-19: Derivation and validation of the HA2T2 COVID-19 mortality risk score. J Am Heart Assoc. 2021; 10(6): e018477. https://dx.doi.org/10.1161/JAHA.120.018477.


46. Ali J., Khan F.R., Ullah R. et al. Cardiac troponin I levels in hospitalized COVID-19 patients as a predictor of severity and outcome: A retrospective cohort study. Cureus. 2021; 13(3): e14061. https://dx.doi.org/10.7759/cureus.14061.


About the Autors

Amina M. Alieva, PhD in Medicine, associate professor of the Department of hospital therapy No. 2 of the Faculty of general medicine, N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia. Address: 117997, Moscow, 1 Ostrovityaninova Str. E-mail: amisha_alieva@mail.ru.
ORCID: https://orcid.org/0000-0001-5416-8579. SPIN-code: 2749-6427
Elena V. Reznik, Dr. med. habil., professor, head of the Department of propaedeutics of internal diseases of the Faculty of general medicine, N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia, general practitioner, cardiologist, doctor of functional diagnostics, ultrasound diagnostics at City Clinical Hospital No. 31 of the Healthcare Department of Moscow. Address: 117997, Moscow, 1 Ostrovityaninova Str. E-mail: elenaresnik@gmail.com. ORCID: https://orcid.org/0000-0001-7479-418X. SPIN-code: 3494-9080. Researcher ID: N-6856-2016
Natalia V. Teplova, Dr. med. habil., professor, head of the Department of clinical pharmacology of the Faculty of general medicine, N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia. Address: 117997, Moscow, 1 Ostrovityaninova Str. ORCID: https://orcid.org/0000-0002-7181-4680
Maxim A. Batov, resident doctor at P.A. Herzen Moscow Scientific and Research Oncological Institute of Oncology – a branch of National Medical Research Center for Radiology. Address: 125284, Moscow, 3 2nd Botkinsky Lane. E-mail: m.batov112@gmail.com. ORCID: https://orcid.org/0000-0002-3780-4358. SPIN-код: 5850-7711
Lidia M. Shnakhova, doctor at I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University). Адрес: 119435, Moscow, 4/1 Bol`shaya Pirogovskaya Str. E-mail: shnakhova_l_m@staff.sechenov.ru
Rosa A. Arakelyan, student at the Faculty of general medicine, N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia. Address: 117997, Moscow, 1 Ostrovityaninova Str. E-mail: Elmira.sharm@yandex.ru. ORCID: https://orcid.org/0000-0002-2500-197X
Irina Evgenievna Baykova, PhD in Medicine, associate professor of the Department of hospital therapy No. 2 of the Faculty of general medicine, N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia. Address: 117997, Moscow, 1 Ostrovityaninova Str. Address: 117997, Moscow, 1 Ostrovityaninova Str. E-mail: 1498553@mail.ru
Gayane G. Totolyan, PhD in Medicine, associate professor of the Department of hospital therapy No. 2 of the Faculty of general medicine, N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia. Address: 117997, Moscow, 1 Ostrovityaninova Str. E-mail: tgg03@mail.ru
Victoria M. Volynkina, PhD in Medicine, associate professor of the Department of hospital therapy No. 2 of the Faculty of general medicine, N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia. Address: 117997, Moscow, 1 Ostrovityaninova Str. ORCID: https://orcid.org/0000-0001-8086-5511
Vladimir A. Kislyakov, PhD in Medicine, associate professor of the Department of hospital therapy No. 2 of the Faculty of general medicine, N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia. Address: 117997, Moscow, 1 Ostrovityaninova Str. E-mail: kvadoctor@mail.ru
Igor G. Nikitin, Dr. med. habil., professor, head of the Department of hospital therapy No. 2 of the Faculty of general medicine, N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia. Address: 117997, Moscow, 1 Ostrovityaninova Str. E-mail: igor.nikitin.64@mail.ru. ORCID: https://orcid.org/0000-0003-1699-0881


Similar Articles

Back to Content

Бионика Медиа